Drug developers and regulators are expanding the use of real world evidence to design, test and review rare disease treatments. But market access challenges persist as payers in the U.S. and Europe continue to express doubts. Our new survey sheds light on the perception gap.
This report is from the Syneos Health Insights Hub, where we generate future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment. Our perspectives are informed by our insights-driven product development model and crafted by subject matter experts focused on real answers to customer challenges to help guide decision making and investment.